Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

15.13 -0.34 (-2.20%)
Streaming Delayed Price Updated: 11:40 AM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced ↗
Biotech companies have always licensed programs, but never so many from one region in particular. 
Via The Motley Fool
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
Summit Therapeutics (NASDAQ:SMMT) Reports Widening Q4 Losses Amid Aggressive Clinical Push ↗
Via Chartmill
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation. 
Via The Motley Fool
What's going on in today's session ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
Summit Therapeutics Stock Dips After Q1 Financial Report ↗
Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know. 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
The next 10 months might be challenging for this biotech. 
Via The Motley Fool
News headline image
Summit (SMMT) Q4 2025 Earnings Call Transcript ↗
Summit (SMMT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
One Fund Discloses $9 Million Ethereum ETF Exit as Crypto Market Downturn Worsens ↗
The iShares Ethereum Trust ETF provides regulated exposure to ether’s price performance for institutional and retail investors alike. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Is SharpLink Gaming Stock a Buy or Sell After Apeiron Capital Sold Its Stake Valued at $23 Million? ↗
SharpLink Gaming connects sports fans and publishers to betting operators through affiliate marketing and data-driven acquisition solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Stocks That Could Soar This Year ↗
These innovative biotechs could have plenty of upside ahead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
2 Biotech Stocks That Could Soar This Year ↗
And, if all goes well, over the next five years as well. 
Via The Motley Fool
News headline image
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital. 
Via The Motley Fool
Topics Stocks
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗
Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗
They haven't peaked yet. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗
The healthcare stock could skyrocket if ivonescimab obtains approval from regulators, but there's still plenty of risk here. 
Via The Motley Fool
News headline image
Don't Buy Summit Therapeutics Until This Big Thing Happen ↗
This biotech company is rolling the dice with a planned regulatory submission. 
Via The Motley Fool
News headline image
2 Monster Stocks in the Making to Buy and Hold ↗
There's still time to get in on these rising stars. 
Via The Motley Fool
News headline image
Summit SMMT Q3 2025 Earnings Call Transcript ↗
Summit SMMT Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗
 
Via Benzinga
News headline image
Why Wall Street Is Backing These 3 Comeback Stocks ↗
Via MarketBeat
News headline image
1 Monster Stock in the Making to Buy and Hold ↗
The company's prospects improve with every clinical win. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.